Nuveen
ELTX icon

Nuveen’s Elicio Therapeutics ELTX Stock Holding History

Nuveen’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9K Buy
+17,888
New +$180K ﹤0.01% 3717
2022
Q2 		– Sell
-3,214
Closed -$69K – 3318
2022
Q1 		$69K Hold
3,214
– – ﹤0.01% 3262
2021
Q4 		$75K Hold
3,214
– – ﹤0.01% 3296
2021
Q3 		$338K Buy
+3,214
New +$347K ﹤0.01% 3236

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Nuveen's ELTX Position: Q2 2026 in Review

Nuveen opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 17,888 shares worth $69.9K. The stake represents ﹤0.01% of the portfolio and ranks #3717 among its holdings. This is a return to the name: Nuveen previously reported a position in ELTX as recently as Q1 2022.

Nuveen first reported a position in ELTX in Q3 2021 and has held it in 4 quarters since. The position peaked at $338K in Q3 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Nuveen held 17,888 shares of Elicio Therapeutics worth $69.9K as of Q2 2026.
  • Elicio Therapeutics was a new Nuveen position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3717 holding.
  • Nuveen first reported a position in Elicio Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • Nuveen's Elicio Therapeutics position peaked at $338K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.